Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).
about
Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET ImagingCajal-like interstitial cells as a novel target in detrusor overactivity treatment: true or myth?Metabolism considerations for kinase inhibitors in cancer treatmentSynthesis and PET studies of [(11)C-cyano]letrozole (Femara), an aromatase inhibitor drugIn vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors modelInfluence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration.PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET.The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.Positron Emission Tomography as a Method for Measuring Drug Delivery to Tumors in vivo: The Example of [(11)C]docetaxelSynthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs.The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.Synthesis of new N-arylpyrimidin-2-amine derivatives using a palladium catalyst.Radiobrominated benzimidazole-quinoline derivatives as Platelet-derived growth factor receptor beta (PDGFRβ) imaging probes.Determination of Three Potential Genotoxic Impurities in Imatinib Mesylate by Gas Chromatography—Mass Spectrometry
P2860
Q26774478-D68E9ED6-C236-40FE-A339-0101785F8E53Q26861452-6F62540F-E51E-4CBC-86F6-0681BC732A09Q34134390-4C9AB8D8-D25C-43DE-BE14-62A8E2C260C1Q35180366-B025E3F8-2430-44FF-BF89-4721EC60B0D1Q35600576-47C70381-561A-41E2-8764-F87C9AD1D5BBQ35609644-682B855E-1312-4C7C-9BEF-A058A6AEC4D8Q35946822-E62EB49F-A9DA-413E-A846-7E4362948295Q37258214-A3BC6CFF-A726-4997-AF5E-05163D9CE1F9Q37281354-2383B31A-CFEB-42C3-945E-A02967D06F36Q37942267-38785C02-4EEE-4DF8-90FC-D53FEC8C5178Q37978157-CAA8F7FF-1373-4656-A872-2F60CD15A2FFQ38068109-13EDA264-1EA8-43CD-98C8-C0DD23511322Q38132396-A22314D9-BFBF-4330-B88A-B645ABD38F12Q38818275-0D9FC482-8B2B-4B40-AA20-BC1C82DD3E87Q39231153-EB33DD45-8AFE-40A9-B025-65403D79E187Q46607082-E0110302-81CB-42AE-9887-A46C136002E2Q55655153-5A4383C6-38BB-4E02-BF46-CB9EBC3A9F3EQ58281286-6AD264ED-CD28-476B-A097-1B89C23AB377
P2860
Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@ast
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@en
type
label
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@ast
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@en
prefLabel
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@ast
Synthesis and positron emissio ...... 11-labeled imatinib (Gleevec).
@en
P2093
P2860
P1476
Synthesis and positron emissio ...... -11-labeled imatinib (Gleevec)
@en
P2093
Colleen Shea
David Alexoff
Joanna S Fowler
Kun-Eek Kil
Lisa Muench
Sung Won Kim
Yu-Shin Ding
P2860
P304
P356
10.1016/J.NUCMEDBIO.2006.11.004
P577
2007-02-01T00:00:00Z